Recludix Pharma Revenue
Biotechnology Research • 
United States • 51-100 Employees
Recludix Pharma revenue & valuation
| Annual revenue | $4,619,970 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $14,800,000 |
| Total funding | $60,000,000 |
Key Contacts at Recludix Pharma
Ryan Diviney
Senior Director Human Resources
Howie Bregman
Sr. Director Of Medicinal Chemistry
Robert Ngo
Director Of Fp&A
Brian Hodous
Co-Founder, Chief Scientific Officer
Sara Mccutchan
Sr. Director, Regulatory Affairs And Medical Writing
Rishi Vaswani
Senior Director
Shirdi Letran
Associate Director Of Translational Sciences
Neil Bifulco
Sr. Director Of Medicinal Chemistry
Allen Sickmier
Senior Director; Head Of Protein Sciences And Structural Biology
Alexandra Gardino
Senior Director
Company overview
| Headquarters | United States |
| Phone number | +18582585445 |
| Websites | |
| NAICS | 541714 |
| Employees | 51-100 |
| Socials |
Recludix Pharma Email Formats
Recludix Pharma uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@recludix.com), used 69.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@recludix.com | 69.1% |
{first initial}{last name} | jdoe@recludix.com | 30.9% |
About Recludix Pharma
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced program is focused on STAT6 (signal transducer and activator of transcription 6) where abnormal activation is found in inflammatory diseases, such as atopic dermatitis, asthma, rheumatoid arthritis and chronic spontaneous urticaria. The company has a strategic collaboration with Sanofi for the development and commercialization of a STAT6 inhibitor. Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional programs. Recludix was named a 2024 Fierce 15 biotech company.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Recludix Pharma has 20 employees across 8 departments.
Departments
Number of employees
Recludix Pharma Tech Stack
Discover the technologies and tools that power Recludix Pharma's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Miscellaneous
JavaScript libraries
CDN
Font scripts
WordPress themes
JavaScript libraries
Programming languages
Blogs
Analytics
SEO
Font scripts
Singapore
Canada
Sweden
ChinaFrequently asked questions
4.8
40,000 users
